Kybella Injections

Shape & Sculpt

Kybella is a targeted fat cell destroyer that tackles that age-old problem of getting rid of chin fat. It’s most popular for dissolving submental fullness or the area beneath your chin that causes saggy jowls and that dreaded double chin. The key to Kybella is in its formula. It’s a synthetic, human-made form of deoxycholic acid, naturally occurring bile that aids in the breakdown of fatty tissue in the body.

When injected into problem spots like that double chin and others—think love handles and bra bulges—it dissolves fat cells in those areas through repeated treatments spaced out over time. What you’re left with are long-lasting results. Those fat cells don’t come back. If you’re interested in learning more about Kybella in Orange County, talk to the experts at the Med Lounge. Face, neck or chin—we can help you attack those problem areas with gusto, once and for all.

Benefits of Botox

Dissolves fat for good

Tightens skin

Natural results

Improvement over time

Long-lasting results

Quick procedure


Quick recovery

Targets problem areas

Extremely safe

Frequently Asked Questions

Kybellais an injectable treatment that targets the fat cells underneath your chin or the submental area. Using a synthetic form of deoxycholic acid, the nonsurgical cosmetic treatment dissolves pockets of fat with impressive precision.

The injectable used in Kybella is a synthetic form of deoxycholic acid, a naturally-occurring bile acid in the body that aids in the breakdown of fatty tissue. When injected into the submental area of the chin or other targeted problem areas, it destroys the fall cells in those areas for good.

Over time and over a number treatments — your provider will likely recommend between 2-4 for optimal results — the injectable keeps those targeted areas from storing or accumulating fat. All that you’re left with is your desired result. 

Kybella is ideal for patients looking to target stubborn pockets of fat where traditional methods haven’t been successful. The double chin is the most popular area to treat, but there are other problem spots that have been proven Kybella-worthy:

  • Bra bulge
  • Love handles
  • Knee fat
  • Saddlebags
  • Lower abdomen


Former liposuction or C-section patients have also turned to Kybella to reduce bulges or pockets of fat as a result of those surgeries. Kybella is also a wonder for those close to their personal goal weight, especially if they’re having difficulties targeting fat loss in problem areas.

If you’re looking to treat larger areas, experts at the Med Lounge can help you decide on nonsurgical alternatives that may better meet your needs over Kybella. If you’re pregnant, may become pregnant or are currently breastfeeding, you should not be receiving Kybella injections.

Before your treatment session, your physician will mark where your injections will go. They will then numb the area to weaken any potential discomfort. Some patients report a burning sensation during their treatment. The treatment itself will take around 15 minutes from start to finish.

Treatments will be scheduled every 4-6 weeks, depending on your injection sites and personalized treatment plan. That treatment plan will determine your Kybella cost. Expect 2-4 treatments for optimal results.

Kybella is very safe. Synthetic deoxycholic acid mimics naturally-produced acids in your body, reducing the chance for reactions post-treatment. Kybella is FDA-approved for use in targeted fat cell reduction in the chin area and has been used globally for years in destroying fat cells in problem spots.

Some swelling is expected post-treatment, but that subsides over time. Pain and redness can usually be managed with over-the-counter pain medications and ice packs to the injection site.

Kybella dissolves fat cells at the injection sites, so results are meant to be long-lasting. Those fat cells don’t come back. They’re destroyed in the process. Once you reach your desired results with Kybella, it’s not expected that you’ll need to return for additional treatments.

See the amazing difference in our clients, before and after treatment.

Click the image to see an enlarged preview.

What to Expect With Kybella

For the best results and to reduce the chance of any side effects after your treatment, our experts at the Med Lounge in Orange County have a few tips around what to expect with Kybella before and after your procedure.


  • Avoid any anti-inflammatories or blood-thinning medications up to two weeks before your treatment. Those include but aren’t limited to: aspirin, Motrin, ibuprofen, and Aleve. If you take daily aspirin for a history of heart disease, talk to your doctor before stopping your aspirin routine.
  • Try to avoid scheduling any special events in the two weeks after your Kybella injections. Some swelling in the targeted areas is expected. It’s natural and temporary.
  • Avoid caffeine, alcohol and high sodium foods at least 48 hours before and 48 hours after your treatment to avoid increased swelling or irritation at the injection sites. 
  • Come to your appointment well-hydrated. Drink plenty of water in the days leading up to your Kybella injections.
  • Consider taking Arnica tablets several days ahead of your treatment. Arnica could help prevent swelling at your injection sites. 
  • Come to your appointment fresh-faced if you’re receiving injections in and around the face. That means no lotions, creams or makeup at the treatment sites.
  • Talk to your provider if you’ve had any cosmetic treatments within the last 14 days before your Kybella treatment. Share a complete medical history, particularly if you’ve had surgeries on your chin, jaw or neck.


  • Avoid rubbing or massaging your face the day after your Kybella treatment. 
  • Keep yourself hydrated by drinking plenty of water in the days following your treatment. 
  • To reduce swelling, apply a cold compress or ice pack to the targeted areas for 20 minutes at a time every hour in the 24 hours after your treatment.
  • If you’re feeling some discomfort, take an over-the-counter painkiller or acetaminophen to help you feel better.
  • Avoid strenuous exercise and intense sun exposure for up to 5 days after your treatment. Rest and relax instead. If you’ve planned any naps, it’s recommended that you sleep on your back with your head elevated for at least three days after treatment. 
  • If it’s your first round of injections, your provider will schedule a series of Kybella injections for maximum benefit. Stick to the schedule your provider shares with you for ideal results. 
  • Call your doctor if you have any serious side effects, such as increased pain or swelling, muscle weakness or difficulty swallowing. Some swelling at the injection site is all normal and temporary.

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information


KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.




KYBELLA® is contraindicated in the presence of infection at the injection sites.


Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.


Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting into or in Proximity to Vulnerable Anatomic Structures

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury

Injection Site Alopecia

Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis

Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.


The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

Botox Option #1

Everything You Need
$ 11
Per Unit
  • Most Popular Option
  • Minimum 10 Units
  • Competitive Pricing

Botox Option #2

Long Term Value
$ 10
Per Unit
  • For Long Term Goals
  • Minimum 30 Units
  • Best Overall Value

Botox Option #3

Yearly Unlimited Membership
$ 999
Per Year
  • Unlimited Visits
  • Refer A Friend Rewards
  • Bonus Benefits
Jane DoeDoe
Jane DoeDoe
Read More
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Johnny Doe
Johnny Doe
Read More
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Jane DoeDoe
Jane DoeDoe
Read More
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information



BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

– Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

– Moderate to severe lateral canthal lines associated with orbicularis oculi activity


– Moderate to severe forehead lines associated with frontalis activity





Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.


BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.


Lack of Interchangeability Between Botulinum Toxin Products

The potency units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).

Dysphagia and Breathing Difficulties

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

Pre-existing Conditions at the Injection Site

Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX® Cosmetic

There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.


The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).


Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by

administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.


There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.


Please see BOTOX® Cosmetic full Prescribing Information including Boxed Warning and Medication Guide.